Carfilzomib Combination Therapy
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
What will happen during the trial?
Patients receive carfilzomib, pomalidomide, and dexamethasone in 28 days treatment cycles. Study treatment continues for as long a their myeloma does not worsen and they do not have unacceptable side effects. After completion of study treatment, patients are followed for up to 2 years.
More Information
- Trial Status
- Active, Not Recruiting
- Trial Phase
- Phase 2
- Enrollment
- 92 patients (estimated)
- Sponsors
- University of Chicago Medicine
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Monoclonal Antibody, CD38
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 449
- NCT Identifier
- NCT01665794
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.